2. Autophagy Metabolic Enzyme/Protease NF-κB Immunology/Inflammation Apoptosis PI3K/Akt/mTOR
  3. Autophagy HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species Apoptosis Akt
  4. Deferoxamine mesylate

Deferoxamine mesylate  (Synonyms: Desferrioxamine B mesylate; DFOM)

Cat. No.: HY-B0988 Purity: 99.71%
COA Handling Instructions

Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19.

For research use only. We do not sell to patients.

Deferoxamine mesylate Chemical Structure

Deferoxamine mesylate Chemical Structure

CAS No. : 138-14-7

Size Price Stock Quantity
Solid + Solvent
10 mM * 1 mL in Water
ready for reconstitution
 USD 66 In-stock
Solution
10 mM * 1 mL in Water USD 66 In-stock
Solid
100 mg USD 60 In-stock
500 mg USD 96 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 164 publication(s) in Google Scholar

Other Forms of Deferoxamine mesylate:

Deferoxamine mesylate Related Antibodies

Top Publications Citing Use of Products

150 Publications Citing Use of MCE Deferoxamine mesylate

WB
Proliferation Assay
RT-PCR
IF

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: Sci Adv. 2022 Mar 4;8(9):eabm1896.  [Abstract]

    PAI1 mRNA expression in iHUVEC treated with increasing doses of either CoCl2, Deferoxamine (DFO), 1, 4-DPCA or DMOG.

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: J Hazard Mater. 2022 Aug 15;436:129043.  [Abstract]

    Deferoxamine (DFOM; 100 μM; 24 h) attenuated the abnormal increase of ROS and LPO in macrophages elicited by CdTe QDs.

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: J Hazard Mater. 2022 Aug 15;436:129043.  [Abstract]

    The specific inhibitor of ferroptosis Fer-1 (100 μM) and Lip-1 (5 μM), and the iron chelator Deferoxamine (DFOM;100 μM) restored the cellular activity of RAW264.7 macrophages after treatment for 24 h.

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2021 Nov 19;13:23-36.  [Abstract]

    The expression of ferroptosis-related proteins in lung cancer cells is detected after Curcumenol treatment with or without Deferoxamine (DFO; 20 μM) by western blotting.

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2021 Nov 19;13:23-36.  [Abstract]

    H1299 cells are treated with Curcumenol with or without Deferoxamine (DFO; 20 μM) for 24 h, and the cell viability is analyzed.

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2021 Mar 8;8(10):2004680.  [Abstract]

    Deferoxamine (DFO; 0.5 μM; for 48 h) could rescue iron overload‐induced cell death in both iHep‐Orgs and iHep.

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2021 Jun;11(6):1513-1525.  [Abstract]

    Deferoxamine (DFO; 10 μM; 72 h) can markedly reverse the cell growth prevented by a2 in MGC-803 and MKN-45 cells.

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2021 Jun 23;40(1):206.  [Abstract]

    Propidium iodide staining confirmed that DFO inhibited metformin-induced cell death in T47D cells Deferoxamine (20 μM; 48 h).

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2020 May 8;5(1):51.  [Abstract]

    Representative results of wound healing after the treatment with the combination of ferroptosis inhibitor DFO and erianin. The expression of EMT markers E-Cadherin and N-Cadherin are examined by western blotting.

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Apr 6;10(11):5107-5119.  [Abstract]

    The cell death induced by the treatment with β-elemene and cetuximab in KRAS mutant CRC cells is almost completely blocked by treatment with ferroptosis rescue agents Deferoxamine (DFO; 20 nM; 24 h), Liproxstatin-1 (Lip-1) or Ferrostatin-1 (Fer-1).

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: J Bone Miner Res. 2020 Jun;35(6):1163-1173.  [Abstract]

    The expression of iron metabolism related protein is assessed by western blot. Protein levels of FPN1 and hepcidin1 in the liver. BL: The baseline group, mice are raised with under the GMF for 4 weeks. HLU: Mice hindlimb are unloaded and raised for 4 weeks. GMF: Mice are kept in a wooden experimental box with the normal GMF for 8 weeks. HyMF: Mice are raised in a GMF-shielded room for 8 weeks. HLU+GMF: HLU mice are reloaded and raised in a wooden box for 4 weeks. HLU+HyMF: HLU mice are reloaded

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: J Bone Miner Res. 2020 Jun;35(6):1163-1173.  [Abstract]

    The expression of iron metabolism related protein was assessed by western blot. Protein levels of TfR1, FTH1 and FPN1 in the tibia. BL: The baseline group, mice are raised with under the GMF for 4 weeks. HLU: Mice hindlimb are unloaded and raised for 4 weeks. GMF: Mice are kept in a wooden experimental box with the normal GMF for 8 weeks. HyMF: Mice are raised in a GMF-shielded room for 8 weeks. HLU+GMF: HLU mice are reloaded and raised in a wooden box for 4 weeks. HLU+HyMF: HLU mice are reloade

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: Cell Res. 2018 Dec;28(12):1171-1185.  [Abstract]

    The FTL- or FTH1-knockdown A375 cells are pretreated with or without DFO (50 μM) for 2 h before CCCP stimulation. The pyroptotic morphology and LDH release are indicated.

    Deferoxamine mesylate purchased from MedChemExpress. Usage Cited in: ACS Appl Mater Interfaces. 2018 Feb 21;10(7):6180-6189.  [Abstract]

    Quantitative analyses confirm the steady increase of blood vessels over the course of implantation of DFO-loading Gp gel.

    View All HIF/HIF Prolyl-Hydroxylase Isoform Specific Products:

    View All Isoforms
    HIF

    View All Akt Isoform Specific Products:

    View All Isoforms
    Akt Akt1 Akt2 Akt3

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19[1][2][3][4][5].

    In Vitro

    Deferoxamine mesylate (1 mM; 16 h or 4 weeks) improves HIF-1α function under hypoxic and hyperglycemic conditions and decreases ROS in MEFs cells[1].
    Deferoxamine mesylate (100 μM; 24 h) increases InsR expression and activity and also induces an increase in p-Akt/total Akt/PKB levels[2].
    Deferoxamine mesylate (5, 10, 25, 50, 100 μM; 7 or 9 days) inhibits the proliferation of tumor-associated MSCs and bone marrow MSCs[3].
    Deferoxamine mesylate (5, 10, 25, 50, 100 μM; 7 days) induces apoptosis of MSCs[3].
    Deferoxamine mesylate (10 μM ; 3 days) influencs the expression of adhesion proteins on MSCs[3].
    Deferoxamine mesylate (100 μM; 24 h) induces autophagy mediated by the level of HIF-1α in SH-SY5Y cells[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Deferoxamine mesylate Related Antibodies

    Western Blot Analysis[1]

    Cell Line: MEFs cells
    Concentration: 1 mM
    Incubation Time: 16 h (hypoxia condition); 4 weeks (hyperglycemic conditions)
    Result: Significantly attenuated the hyperglycemia-associated increase in ROS levels under hypoxic high glucose conditions.
    Notably increased normoxic HIF transactivation in MEFs under both high glucose and normal glucose conditions.

    Western Blot Analysis[2]

    Cell Line: HepG2 cells
    Concentration: 100 µM
    Incubation Time: 24 h
    Result: Showed a twofold increase of InsR mRNA levels in cells.
    Increased by twofold InsR binding activity at the half-maximal concentration of 1.1 nM.

    Cell Proliferation Assay[3]

    Cell Line: TAMSCs and BMMSCs (all isolated from Male C57BL/6J mice (8 week-old; EG-7 induced tumor model))
    Concentration: 5, 10, 25, 50, 100 µM
    Incubation Time: 7 days (TAMSCs); 9 days (BMMSCs)
    Result: Inhibited the growth of TAMSCs and BMMSCs, and most cells are died at day 7 or 9 when exposed to 50 and 100 µM dose.

    Apoptosis Analysis[3]

    Cell Line: TAMSCs, BMMSCs
    Concentration: 5, 10, 25, 50, 100 µM
    Incubation Time: 7 days
    Result: Exhibited proapoptotic effect on TAMSCs and BMMSCs cells.

    Western Blot Analysis[3]

    Cell Line: TAMSCs, BMMSCs
    Concentration: 10 µM
    Incubation Time: 3 days
    Result: Remarkably decreased VCAM-1 expression in both TAMSCs and BMMSCs.

    Cell Autophagy Assay[4]

    Cell Line: SH-SY5Y cells
    Concentration: 100 µM
    Incubation Time: 24 h
    Result: Increased the ratio of LC3-II/I, an indicator of autophagy, which effects were blocked when autophagy-related gene Beclin 1 was suppressed by Beclin 1 siRNA transfection.
    Caused a time and dose-dependent increase of HIF-1a, accompanied by the induction of autophagy.
    In Vivo

    Deferoxamine mesylate (6.57 μg/per; drip-on; once daily for 21 days) enhances wound healing and increases neovascularization in aged or diabetic mice[1].
    Deferoxamine mesylate (200 mg/kg; i.p.; daily for 2 weeks) results in HIF-1α stabilization and increases glucose uptake, hepatic InsR expression, and signaling in vivo[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Aged (21-month-old) and diabetic (12-week-old) C57BL/6J mice (excisional wound model)[1].
    Dosage: 6.57 µg/per (10 uL of 1 mM)
    Administration: Drip-on; once daily for 21 days.
    Result: Displayed significantly accelerated healing and increased neovascularization in both aged and diabetic mice model.
    Animal Model: Male Sprague-Dawley rats (180-200 g)[2].
    Dosage: 200 mg/kg
    Administration: Intraperitoneal injection; daily for 2 weeks.
    Result: Significantly increased hepatic HIF-1α protein levels, InsR protein levels, as well as Akt/PKB and activated Akt/PKB were significantly higher in the liver.
    Clinical Trial
    Molecular Weight

    656.79

    Appearance

    Solid

    Formula

    C26H52N6O11S
    CAS No.
    SMILES

    O=C(N(CCCCCN)O)CCC(NCCCCCN(C(CCC(NCCCCCN(C(C)=O)O)=O)=O)O)=O.CS(=O)(O)=O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    Solvent & Solubility
    In Vitro: 

    H2O : 250 mg/mL (380.64 mM; Need ultrasonic)

    DMSO : 100 mg/mL (152.26 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.5226 mL 7.6128 mL 15.2256 mL
    5 mM 0.3045 mL 1.5226 mL 3.0451 mL
    10 mM 0.1523 mL 0.7613 mL 1.5226 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  PBS

      Solubility: 5.56 mg/mL (8.47 mM); Clear solution; Need ultrasonic

    *All of the co-solvents are available by MedChemExpress (MCE).
    Purity & Documentation

    Purity: 99.86%

    COA (241 KB) HNMR (299 KB) RP-HPLC (242 KB) MS (69 KB) Elemental Analysis Report (99 KB)

    Handling Instructions (2659 KB)
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Deferoxamine mesylate Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Keywords:

    Deferoxamine138-14-7Desferrioxamine B DFOMAutophagyHIF/HIF Prolyl-HydroxylaseReactive Oxygen SpeciesApoptosisAktHypoxia-inducible factorsHIFsHIF-PHPKBProtein kinase Bdiabetes mellitusneovascularizationcancerAlzheimer’s diseaseMEFsTAMSCsBMMSCsCOVID-19PDSH-SY5YInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Deferoxamine mesylate
    Cat. No.:
    HY-B0988
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.